1. Home
  2. TUYA vs TBPH Comparison

TUYA vs TBPH Comparison

Compare TUYA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tuya Inc. each representing one

TUYA

Tuya Inc. each representing one

HOLD

Current Price

$1.87

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$17.05

Market Cap

908.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TUYA
TBPH
Founded
2014
2013
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
908.9M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
TUYA
TBPH
Price
$1.87
$17.05
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$3.49
$18.40
AVG Volume (30 Days)
544.3K
402.8K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
5.40%
N/A
EPS Growth
N/A
279.13
EPS
N/A
N/A
Revenue
N/A
$15,386,000.00
Revenue This Year
$13.76
$8.46
Revenue Next Year
$11.90
N/A
P/E Ratio
$27.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.61
$13.08
52 Week High
$2.73
$21.03

Technical Indicators

Market Signals
Indicator
TUYA
TBPH
Relative Strength Index (RSI) 56.12 63.76
Support Level $1.72 $16.80
Resistance Level $2.00 $17.17
Average True Range (ATR) 0.06 0.05
MACD 0.01 0.00
Stochastic Oscillator 61.08 82.05

Price Performance

Historical Comparison
TUYA
TBPH

About TUYA Tuya Inc. each representing one

Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness. All the Group's revenue are derived from within the PRC.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: